Activation of Epidermal Growth Factor Receptor Sensitizes Glioblastoma Cells to Hypoxia-Induced Cell Death
Authors:
- Anna-Luisa LugerALAnna-Luisa Luger
- Nadja I. LorenzNLNadja I. Lorenz
- Hans UrbanHUHans Urban
- Iris DivéIDIris Divé
- Anna L. EngelAEAnna L. Engel
- Florian StrassheimerFSFlorian Strassheimer
- Katja DettmerKatja Dettmer
- Pia S. ZeinerPZPia S. Zeiner
- Shabnam ShaidSSShabnam Shaid
- Nina StruveNSNina Struve
- Malte KriegsMKMalte Kriegs
- Ute HofmannUHUte Hofmann
Open Access
Abstract
Background: The epidermal growth factor receptor (EGFR) signaling pathway is genetically activated in approximately 50% of glioblastomas (GBs). Its inhibition has been explored clinically but produced disappointing results, potentially due to metabolic effects that protect GB cells against nutrient deprivation and hypoxia. Here, we hypothesized that EGFR activation could disable metabolic adaptation and define a GB cell population sensitive to starvation. Methods: Using genetically engineered GB cells to model different types of EGFR activation, we analyzed changes in metabolism and cell survival under conditions of the tumor microenvironment. Results: We found that expression of mutant EGFRvIII as well as EGF stimulation of EGFR-overexpressing cells impaired physiological adaptation to starvation and rendered cells sensitive to hypoxia-induced cell death. This was preceded by adenosine triphosphate (ATP) depletion and an increase in glycolysis. Furthermore, EGFRvIII mutant cells had higher levels of mitochondrial superoxides potentially due to decreased metabolic flux into the serine synthesis pathway which was associated with a decrease in the NADPH/NADP+ ratio. Conclusions: The finding that EGFR activation renders GB cells susceptible to starvation could help to identify a subgroup of patients more likely to benefit from starvation-inducing therapies.Keywords
Funding Information
- The Dr. Senckenberg Institute of Neurooncology is supported by the Dr. Senckenberg Foundation. (see above)
- ALL and ID haves received funding from the Medical Faculty of the Goethe University Frankfurt (Frankfurt research funding, FFF) via the program "Patenschaftsmodell” and a fellowship in the program “Clinician Scientist” by the Else Kröner-Fresenius-St (see above)
- ALE has received a scholarship by the Adolf Gutknecht trust. (see above)
- PSZ has also received funding from the Medical Faculty of the Goethe University Frankfurt (FFF) via the programs "Patenschaftsmodell” and “Nachwuchsforscher”. (see above)
- UH is supported by the Robert-Bosch Foundation, Stuttgart, Germany. (see above)
- JPS has received funding by the German Research Foundation (DFG) (DFG 2175/1-1)
- J.P.S. and M.W.R. have received funding by the State of Hessen within the LOEWE program. (see above)
- MWR has received a fellowship from the University Cancer Center Frankfurt (UCT) as well as from the Medical Faculty of the Goethe University Frankfurt (FFF) via the programs "Nachwuchsforscher” and “Clinician Scientists”. (see above)
This publication has 26 references indexed in Scilit:
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015Neuro-Oncology, 2018
- A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913Neuro-Oncology, 2017
- Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for GlioblastomaJAMA, 2015
- Current Therapeutic Advances Targeting EGFR and EGFRvIII in GlioblastomaFrontiers in Oncology, 2015
- The Somatic Genomic Landscape of GlioblastomaCell, 2013
- The epidermal growth factor receptor variant III (EGFRvIII): where wild things are alteredThe FEBS Journal, 2013
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma SamplesClinical Cancer Research, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005